Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease

Figure 5 The effects of semaglutide on major kidney and cardiovascular outcomes in the Evaluate Renal Function with Semaglutide Once Weekly trial. Evaluate Renal Function with Semaglutide Once Weekly kidney outcome- New or worsening nephropathy: Macroalbuminuria, doubling of serum creatinine with estimated glomerular filtration rate (eGFR ≤ 45), initiation of renal replacement, or renal death. Major CV events: Major CV events including CV death, non-fatal myocardial infarction, or non-fatal stroke and heart failure with secondary/exploratory outcomes included hospitalization for heart failure; CV: Cardiovascular; HF: Heart failure; FLOW: Evaluate Renal Function with Semaglutide Once Weekly.